{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:29:46Z","timestamp":1762100986609},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1038\/leu.2009.193","type":"journal-article","created":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T17:01:27Z","timestamp":1254416487000},"page":"6-12","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history"],"prefix":"10.1038","volume":"24","author":[{"given":"E","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"La Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"BFleu2009193_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290\u2013293.","journal-title":"Nature"},{"key":"BFleu2009193_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/306277a0","volume":"306","author":"CR Bartram","year":"1983","unstructured":"Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306: 277\u2013280.","journal-title":"Nature"},{"key":"BFleu2009193_CR3","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330\u20131340.","journal-title":"N Engl J Med"},{"key":"BFleu2009193_CR4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.18553\/jmcp.2007.13.s8-a.4","volume":"13","author":"J Sessions","year":"2007","unstructured":"Sessions J . Chronic myeloid leukemia in 2007. J Manag Care Pharm 2007; 13: 4\u20137.","journal-title":"J Manag Care Pharm"},{"key":"BFleu2009193_CR5","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343\u20133356.","journal-title":"Blood"},{"key":"BFleu2009193_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561\u2013566.","journal-title":"Nat Med"},{"key":"BFleu2009193_CR7","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809\u20131820.","journal-title":"Blood"},{"key":"BFleu2009193_CR8","unstructured":"National Comprehensive Cancer Network. NCCN: clinical practice guidelines in oncology. Chronic Myelogenous Leukemia. Version (V.1.2010), 2009."},{"key":"BFleu2009193_CR9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054\u20131061.","journal-title":"Leukemia"},{"key":"BFleu2009193_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"SG O'Brien","year":"2008","unstructured":"O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes T, Radich JP et al. International Randomized Study of Interferon and STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008; 112: 76.","journal-title":"Blood"},{"key":"BFleu2009193_CR11","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Ros\u00e9e P, M\u00fcller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190\u20132196.","journal-title":"Leukemia"},{"key":"BFleu2009193_CR12","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Ros\u00e9e P . Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321\u20131331.","journal-title":"Leukemia"},{"key":"BFleu2009193_CR13","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF . Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018\u20131029.","journal-title":"Lancet Oncol"},{"key":"BFleu2009193_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/cncr.24066","volume":"115","author":"HM Kantarjian","year":"2009","unstructured":"Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009; 115: 551\u2013560.","journal-title":"Cancer"},{"key":"BFleu2009193_CR15","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","volume":"113","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Kantarjian H, O'Brien S, Wierda W, Faderl S, Garcia-Manero G et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 2008; 113: 2154\u20132160.","journal-title":"Blood"},{"key":"BFleu2009193_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors\u2014review and recommendations for \u2018harmonizing\u2019 current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28\u201337.","journal-title":"Blood"},{"issue":"Suppl 2","key":"BFleu2009193_CR17","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3816\/CLM.2007.s.002","volume":"7","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H . Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma 2007; 7 (Suppl 2): S51\u2013S57.","journal-title":"Clin Lymphoma Myeloma"},{"key":"BFleu2009193_CR18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood.V112.11.130.130","volume":"112","author":"JE Cortes","year":"2008","unstructured":"Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim D-W et al. A phase III, randomized, open-label study of 400 versus 800\u2009mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study. Blood 2008; 112: 130\u2013131.","journal-title":"Blood"},{"key":"BFleu2009193_CR19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.V112.11.75.75","volume":"112","author":"M Baccarani","year":"2008","unstructured":"Baccarani M, Castagnetti F, Simonsson B, Porkka K, Haznedaroglu IC, Nagler A et al. Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of a European LeukemiaNet prospective study comparing 400 and 800\u2009mg front-line. Blood 2008; 112: 75.","journal-title":"Blood"},{"key":"BFleu2009193_CR20","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","volume":"11","author":"M Golemovic","year":"2005","unstructured":"Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005; 11: 4941\u20134947.","journal-title":"Clin Cancer Res"},{"key":"BFleu2009193_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFleu2009193_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/10428190801896103","volume":"49","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Rix U, Superti-Furga G . Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49: 615\u2013619.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2009193_CR23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood.V112.11.170.170","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes J, O'Brien S, Jones D, Ferrajoli A, Konopleva M, Borthakur G et al. Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 2008; 112: 170.","journal-title":"Blood"},{"key":"BFleu2009193_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1182\/blood-2007-12-128835","volume":"112","author":"G Rosti","year":"2008","unstructured":"Rosti G, Castagnetti F, Poerio A, Breccia M, Levato L, Capucci A et al. High and early rates of cytogenetic and molecular response with nilotinib 800\u2009mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party. Blood 2008; 112: 73\u201374.","journal-title":"Blood"},{"key":"BFleu2009193_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399\u2013401.","journal-title":"Science"},{"key":"BFleu2009193_CR26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V112.11.74.74","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes J, O'Brien S, Borthakur G, Jones D, Ravandi F, Koller C et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood 2008; 112: 74.","journal-title":"Blood"},{"key":"BFleu2009193_CR27","unstructured":"Sprycel (dasatinib) [package insert]. Bristol-Myers Squibb Company: Princeton, NJ, 2007."},{"key":"BFleu2009193_CR28","unstructured":"Sprycel (dasatinib) [package insert]. Bristol-Myers Squibb Company: Princeton, NJ, 2009."},{"key":"BFleu2009193_CR29","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303\u20132309.","journal-title":"Blood"},{"key":"BFleu2009193_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Baccarani M, Lipton J, Matloub Y, Sinha R, Stone RM et al. Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: A two-year update of the START-C study. Haematologica 2008; 93: 372.","journal-title":"Haematologica"},{"key":"BFleu2009193_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3324\/haematol.13015","volume":"93","author":"P Rousselot","year":"2008","unstructured":"Rousselot P, Corm S, Paquette R, Bleickardt E, Dejardin D, Kantarjian H et al. Dasatinib compared with high-dose imatinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) after failure of standard-dose imatinib\u2014a two-year update of the START-R study. Haematologica 2008; 93: 48.","journal-title":"Haematologica"},{"key":"BFleu2009193_CR32","doi-asserted-by":"publisher","first-page":"358s","DOI":"10.1200\/JCO.2007.12.5062","volume":"25","author":"NP Shah","year":"2007","unstructured":"Shah NP, Kim DW, Kantarjian HMea . Dasatinib 50 or 70\u2009mg BID compared to 100 or 140\u2009mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034. J Clin Oncol 2007; 25: 358s.","journal-title":"J Clin Oncol"},{"key":"BFleu2009193_CR33","unstructured":"Tasigna (nilotinib) [package insert] Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2007."},{"key":"BFleu2009193_CR34","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.V112.11.1112.1112","volume":"112","author":"HM Kantarjian","year":"2008","unstructured":"Kantarjian HM, Giles F, Bhalla KN, Larson RA, Gattermann N, Ottmann OG et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008; 112: 1112.","journal-title":"Blood"},{"key":"BFleu2009193_CR35","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V112.11.1103.1103","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Kantarjian HM, Baccarani M, le Coutre P, Haque A, Gallagher NJ et al. Minimal cross intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase (CML-CP) or accelerated phase (CML-AP). Blood 2008; 112: 1103.","journal-title":"Blood"},{"key":"BFleu2009193_CR36","first-page":"371","volume":"93","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, M\u00fcller MC, Cortes JE, Kim DW, Matloub Y, Ploughman L et al. Dasatinib efficacy after imatinib failure by dosing schedule and baseline BCR-ABL mutation status in patients with chronic myeloid leukemia in chronic phase (CML-CP). Haematologica 2008; 93: 371\u2013372.","journal-title":"Haematologica"},{"key":"BFleu2009193_CR37","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"T Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, Soverini S, Kim D, M\u00fcller M et al. Impact of baseline BCR-ABL mutations on response to nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP). J Clin Oncol 2009; 27: 4204\u20134210.","journal-title":"J Clin Oncol"},{"key":"BFleu2009193_CR38","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332\u20132338.","journal-title":"Blood"},{"key":"BFleu2009193_CR39","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1586\/14737140.8.9.1387","volume":"8","author":"R Tanaka","year":"2008","unstructured":"Tanaka R, Kimura S . Abl tyrosine kinase inhibitors for overriding Bcr-Abl\/T315I: from the second to third generation. Expert Rev Anticancer Ther 2008; 8: 1387\u20131398.","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFleu2009193_CR40","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.V112.11.1112.1112","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes J, Khoury HJ, Corm S, Nicolini F, Lipton J, Jones D et al. Safety and efficacy of subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia patients with the T315I mutation\u2014results of an ongoing multicenter phase 2\/3 study. Blood 2008; 112: 1112\u20131113.","journal-title":"Blood"},{"key":"BFleu2009193_CR41","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908\u20133914.","journal-title":"J Clin Oncol"},{"key":"BFleu2009193_CR42","doi-asserted-by":"publisher","first-page":"680s","DOI":"10.1200\/JCO.2007.11.8604","volume":"25","author":"JH Lipton","year":"2007","unstructured":"Lipton JH, Sriharsha L, Bogomilsky S, Casciaro L, Keating A, Messner H et al. Pleural effusions in patients treated with dasatinib: results from two institutions, risk factors and management. J Clin Oncol 2007; 25: 680s.","journal-title":"J Clin Oncol"},{"key":"BFleu2009193_CR43","doi-asserted-by":"crossref","first-page":"680s","DOI":"10.1200\/jco.2007.25.18_suppl.17501","volume":"25","author":"KT Carpiuc","year":"2007","unstructured":"Carpiuc KT, Stephens JM, Liou SY, Botteman MF . Incidence of grade 3\/4 adverse events in imatinib resistant\/intolerant chronic phase CML (CP-CML): a comparison of nilotinib and dasatinib. J Clin Oncol 2007; 25: 680s.","journal-title":"J Clin Oncol"},{"key":"BFleu2009193_CR44","doi-asserted-by":"crossref","first-page":"16a","DOI":"10.1182\/blood.V110.11.16.16","volume":"110","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Neubauer A, Mueller MC, Napieralski S, Erben P, Bostel T et al. Sustained molecular responses with interferon alpha 2a maintenance therapy after imatinib plus IFN induction treatment for chronic phase chronic myelogenous leukemia. Blood 2007; 110: 16a\u201317a.","journal-title":"Blood"},{"key":"BFleu2009193_CR45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V112.11.76.76","volume":"112","author":"F Mahon","year":"2008","unstructured":"Mahon F, Huguet F, Guilhot F, Legros L, Nicolini FE, Charbonnier A et al. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from the multicentre \u2018Stop Imatinib\u2019 (STIM) study. Blood 2008; 112: 76.","journal-title":"Blood"},{"key":"BFleu2009193_CR46","doi-asserted-by":"publisher","first-page":"386s","DOI":"10.1200\/JCO.2006.09.5448","volume":"26","author":"N Jain","year":"2008","unstructured":"Jain N, Kantarjian HM, Garcia-Manero G, Borthakur G, Ebarb T, Cortes JE . Synthetic tumor-specific breakpoint peptide vaccine in patients (pts) with chronic myeloid leukemia (CML) and minimal residual disease: a phase II trial. J Clin Oncol 2008; 26: 386s.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2009193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2009193","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2009193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:18:01Z","timestamp":1648729081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2009193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["BFleu2009193"],"URL":"https:\/\/doi.org\/10.1038\/leu.2009.193","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,1]]},"assertion":[{"value":"28 April 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}